Clinical trials: CAR-T Cell Therapy
Immune Effector Cell Associated Hematotoxicity
Safety and Efficacy of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in the Treatment of Long-Term Cytopenia After CAR-T Therapy
This study is a single arm, open label, exploratory clinical study aimed at evaluating the efficacy, and safety of allogeneic umbilical cord blood-derived mesenchymal stem cells in the treatment of long-term cytopenia after CAR-T…
- Trial name
- MSC-ICAHT (NCT07212335)
- Testing
- Mesenchymal Stem Cell Infusion
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Unresectable or Metastatic Clear Cell Renal Cell Carcinoma
The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell Carcinoma
CLEAR CAR-T cell injection (ET-970) is an engineered CD70-targeting allogeneic Chimeric Antigen Receptor T-Cell (CAR-T cell). This is a multi-center, single-arm, open-label, early exploratory clinical study.
- Trial name
- NCT07645690
- Testing
- CLEAR CAR-T cell injection
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
B-Cell Non-Hodgkin Lymphoma
Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy
This phase II trial studies how well anakinra works in decreasing the occurrence of cytokine release syndrome (CRS) and damage to the nerves (neurotoxicity) in patients with B-cell non-Hodgkin lymphoma who are receiving CD-19…
- Trial name
- NCT04359784
- Testing
- Anakinra, X-Ray Imaging, Positron Emission Tomography
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Fred Hutchinson Cancer Center
Hematological Malignancies
Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
This is a long-term follow-up study for participants treated with Galapagos (GLPG) CAR T-cell therapies to evaluate the long-term safety and efficacy of GLPG CAR T-cell products for 15 years post infusion.
- Trial name
- Hesperia (NCT06652633)
- Testing
- GLPG CAR T-cell therapy
- Where
- 11 sites in United States, Belgium and 3 more
- Volunteers
- 546 people
- Sponsor
- Lakefront Biotherapeutics NV
Autoimmune Diseases, SLE - Systemic Lupus Erythematosus
RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases
This is a single-arm, open-label, phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-05, a universal CD19/BCMA dual-targeting chimeric antigen receptor T-cell…
- Conditions
- Autoimmune Diseases, SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis, IIM- Idiopathic Inflammatory Myopathies
- Trial name
- NCT07674147
- Testing
- RD06-05 CART Cell Infusion
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Relapsed and/or Refractory Acute Lymphoblastic Leukemia, Relapsed and/or Refractory B-cell Non-Hodgkin's Lymphoma
CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma
A study of CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma
- Trial name
- NCT04609241
- Testing
- CD79b CAR-T Cells
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Zhejiang University
Lymphoma, B-Cell, Chronic Lymphocytic Leukemia
FT819 in Subjects With B-cell Malignancies
This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia.
- Conditions
- Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia
- Trial name
- NCT04629729
- Testing
- FT819, Cyclophosphamide, Fludarabine
- Where
- 18 sites in United States
- Volunteers
- 54 people
- Sponsor
- Fate Therapeutics
Colorectal Cancer, Esophagus Cancer
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
This is a single-arm, open, dose-increasing phase I clinical study to explore the safety, tolerability and pharmacokinetic characteristics of the drug C-13-60 cells, and preliminarily observe the efficacy of the drug in CEA…
- Conditions
- Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreas Cancer
- Trial name
- NCT06043466
- Testing
- CEA-targeted CAR-T cells
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Metastatic Prostate Cancer
Study of AZD0754 in Participants With Metastatic Prostate Cancer
The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.
- Trial name
- APOLLO (NCT06267729)
- Testing
- AZD0754, AZD2287
- Where
- 15 sites in United States, Australia and 1 more
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Multiple Myeloma
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of the study is to characterize safety of JNJ-68284528 and establish the recommended Phase 2 dose (RP2D) (Phase 1b) and to evaluate the efficacy of JNJ-68284528 (Phase 2).
- Trial name
- CARTITUDE-1 (NCT03548207)
- Testing
- JNJ-68284528
- Where
- 21 sites in United States, Japan
- Volunteers
- 126 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM)
This is an open label, single-arm, Phase 2 study to evaluate the efficacy and safety of Anti-BCMA/GPRC5D CAR-T in subjects with relapsed and refractory multiple myeloma.
- Trial name
- NCT05509530
- Testing
- anti-BCMA/GPRC5D CAR-T CELL
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Xuzhou Medical University
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Follicular Lymphoma
Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients
The goal of this clinical trial is to study the feasibility and efficacy of anti-CD22:TCRz:4-1BB chimeric antigen receptor (CAR)-modified T (CAR-T) cells in treating recurrent patients with refractory or resistant lymphoma to…
- Conditions
- Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Stage III/IV Adult Diffuse Large Cell Lymphoma
- Trial name
- MendCART (NCT02721407)
- Testing
- Retroviral vector-transduced autologous T cells to express CD22-specific CARs
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xinqiao Hospital of Chongqing
Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
This phase I trial tests the safety, side effects and best dose of anti-CD19/20/22 chimeric antigen receptor (CAR) T cells (TriCAR19.20.22 T cells) and how well they work in treating patients with non-Hodgkin lymphoma, acute…
- Conditions
- Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Trial name
- NCT07166419
- Testing
- Autologous Anti-CD19/CD20/CD22 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Acute Myeloid Leukemia (AML), CAR-T Cell Therapy
A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
This is a single-center, open-label study to evaluate the safety and efficacy of A-CAR028 in relapsed/refractory acute myeloid leukemia patients
- Trial name
- NCT07198867
- Testing
- A-CAR028
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Neoplasms, Hematologic Neoplasms
RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T therapy for patients with CD7-positive relapsed or refractory T-ALL/LBL, and to evaluate the…
- Conditions
- Neoplasms, Hematologic Neoplasms, Hematologic Diseases
- Trial name
- NCT05902845
- Testing
- RD13-02 cell infusion
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Xiaoyu Zhu
Lupus Nephritis, Lupus Nephritis (LN)
Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With Refractory Lupus Nephritis
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of CD19 CAR-T cell therapy (TranspoCART19) in adults with refractory lupus nephritis.
- Trial name
- CART-NEL (NCT07799116)
- Testing
- TranspoCART19
- Where
- 8 sites in Spain
- Volunteers
- 10 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Relapsed Refractory Multiple Myeloma (RRMM)
BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM
This study is a prospective, single-arm, multicenter trial designed to evaluate the hematologic response rate and safety of BCMA/CD3 bispecific antibody bridging therapy prior to CAR-T cell infusion in patients with…
- Trial name
- CM336-001 (NCT07407010)
- Testing
- CM336 (BCMA/CD3 bispecific antibody)
- Volunteers
- 10 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
B Cell Lymphoma (BCL)
Multi-CAR-T Cells Targeting B Cell Lymphomas
This study aims to evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting B cell surface molecules including CD19 and alternative CARTs as booster and…
- Trial name
- NCT04429438
- Testing
- 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
T Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma
The purpose of this study is to test the safety and efficacy of AUTO4 a chimeric antigen receptor (CAR) T cell treatment targeting TRBC1 in patients with relapsed or refractory TRBC1 positive selected T-Non-Hodgkin Lymphoma (NHL).
- Conditions
- T Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma
- Trial name
- NCT03590574
- Testing
- AUTO4
- Where
- 5 sites in Spain, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Autolus Limited
Colorectal Cancer, Metastatic Liver Cancer
Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases
Recurrence of liver metastasis in colorectal cancer after R0 resection is mainly due to the invisible minimal residual disease, which are the main factors leading to metastasis and recurrence.
- Trial name
- NCT05240950
- Testing
- Anti-CEA CAR-T Cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Changhai Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.